REGENERON PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, Accumulated Amortization
REGENERON PHARMACEUTICALS, INC. (REGN) had Finance Lease, Right-of-Use Asset, Accumulated Amortization of $162.90 million as of 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Notes › Leases › Assets and Liabilities, Lessee
us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization · last filed 2026-02-04
- 2025-12-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $162.90M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $148.40M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $133.90M.
- 2022-12-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $119.40M.
| Period end | Finance Lease, Right-of-Use Asset, Accumulated Amortization |
|---|---|
| 2025-12-31 | $162.90M 10-K · filed 2026-02-04 |
| 2024-12-31 | $148.40M 10-K · filed 2026-02-04 |
| 2023-12-31 | $133.90M 10-K · filed 2025-02-05 |
| 2022-12-31 | $119.40M 10-K · filed 2024-02-05 |
| 2021-12-31 | $104.90M 10-K · filed 2023-02-06 |
| 2020-12-31 | $90.50M 10-K · filed 2022-02-07 |
| 2019-12-31 | $76.10M 10-K · filed 2021-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |